A Phase 4 interventional study of MenACYW conjugate vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 2 sites in Argentina. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent meningococcal conjugate vaccines Nimenrix® or Menveo® during infancy to protect against invasive meningococcal disease (IMD).
Participants received a single dose of MenQuadfi® at Visit 1. Participants provided 2 blood samples, one at D01 (Visit 1) pre-vaccination and another at D31 (Visit 2) post-vaccination for the immunogenicity assessments.
Study included 2 visits at D01 (Visit 1) and at D31 (Visit 2), and 1 Telephone call (TC) for safety follow-up at D09 post-study vaccination.
Study duration was approximately 30 days (+14 days) per participant
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants received a single booster dose of the MenACYW conjugate vaccine with an interval of at least 2 months after the last vaccination with Nimenrix® or Menveo® received during infancy before 12 months of age
Biological: MenACYW conjugate vaccine
Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
Also known as: MenQuadfi®
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Assay Using Human Complement
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA).
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 Against Meningococcal Serogroups A, C, Y, and W
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Percentage of Participants With Vaccine Seroresponse by Serum Bactericidal Assay Using Human Complement
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). hSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:16 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post vaccination on Day 1)
Geometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement (rSBA)
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA).
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Percentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Percentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Percentage of Participants With Vaccine Seroresponse by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). rSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:32 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Geometric Mean Concentrations (GMCs) of Antibodies Against Tetanus Toxoid
Geometric Mean Concentrations (GMCs) of anti-tetanus toxoid antibodies was measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent assay.
Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.
Time frame: Up to 30 minutes post-vaccination on Day 1
Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site tenderness, injection site erythema and injection site swelling. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability.
Time frame: Up to 7 days post-vaccination on Day 1
Number of Participants With Unsolicited Adverse Events
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.
Time frame: Up to 30 days post-vaccination on Day 1
Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.
Time frame: From vaccination (Day 1) up to 30 days post vaccination, 31 days
This study was conducted at 2 investigational sites in Argentina between 07 September 2023 to 09 September 2024.
| Milestone | MenACYW Conjugate Vaccine |
|---|---|
| Started | 71 |
| Safety analysis set (safas) | 69 |
| Completed | 68 |
| Not completed | 3 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Withdrawal by participant's parents/legally acceptable representatives | 2 |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A: Day 1 | 72.1 (59.2 to 82.9) |
| Serogroup A: Day 31 | 100 (93.8 to 100) |
| Serogroup C: Day 1 | 60.3 (47.2 to 72.4) |
| Serogroup C: Day 31 | 100 (94.1 to 100) |
| Serogroup Y: Day 1 | 67.7 (54.7 to 79.1) |
| Serogroup Y: Day 31 | 100 (93.2 to 100) |
| Serogroup W: Day 1 | 73.4 (60.9 to 83.7) |
| Serogroup W: Day 31 | 100 (93.8 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA).
| Titer | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A: Day 1 | 14.0 (10.1 to 19.4) |
| Serogroup A: Day 31 | 244 (163 to 366) |
| Serogroup C: Day 1 | 12.3 (8.29 to 18.2) |
| Serogroup C: Day 31 | 1072 (805 to 1426) |
| Serogroup Y: Day 1 | 14.0 (9.70 to 20.2) |
| Serogroup Y: Day 31 | 945 (683 to 1309) |
| Serogroup W: Day 1 | 16.9 (11.8 to 24.2) |
| Serogroup W: Day 31 | 953 (712 to 1275) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A: Day 1 | 96.7 (88.7 to 99.6) |
| Serogroup A: Day 31 | 100 (93.8 to 100) |
| Serogroup C: Day 1 | 76.2 (63.8 to 86.0) |
| Serogroup C: Day 31 | 100 (94.1 to 100) |
| Serogroup Y: Day 1 | 85.5 (74.2 to 93.1) |
| Serogroup Y: Day 31 | 100 (93.2 to 100) |
| Serogroup W: Day 1 | 87.5 (76.8 to 94.4) |
| Serogroup W: Day 31 | 100 (93.8 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A | 91.1 (80.4 to 97.0) |
| Serogroup C | 100 (93.9 to 100) |
| Serogroup Y | 96.1 (86.5 to 99.5) |
| Serogroup W | 100 (93.7 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). hSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:16 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A | 91.1 (80.4 to 97.0) |
| Serogroup C | 100 (93.9 to 100) |
| Serogroup Y | 96.1 (86.5 to 99.5) |
| Serogroup W | 100 (93.7 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA).
| Titer | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A: Day 1 | 82.3 (33.3 to 203) |
| Serogroup A: Day 31 | 4715 (3547 to 6268) |
| Serogroup C: Day 1 | 11.6 (6.54 to 20.7) |
| Serogroup C: Day 31 | 3676 (2707 to 4990) |
| Serogroup Y: Day 1 | 30.9 (15.6 to 61.2) |
| Serogroup Y: Day 31 | 5198 (4091 to 6604) |
| Serogroup W: Day 1 | 28.0 (14.7 to 53.5) |
| Serogroup W: Day 31 | 9329 (6627 to 13132) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A: >=1:8: Day 1 | 56.4 (42.3 to 69.7) |
| Serogroup A: >=1:128: Day 1 | 54.5 (40.6 to 68.0) |
| Serogroup A: >=1:8: Day 31 | 100 (94.4 to 100) |
| Serogroup A: >=1:128: Day 31 | 100 (94.4 to 100) |
| Serogroup C: >=1:8: Day 1 | 39.3 (27.1 to 52.7) |
| Serogroup C: >=1:128: Day 1 | 24.6 (14.5 to 37.3) |
| Serogroup C: >=1:8: Day 31 | 100 (94.4 to 100) |
| Serogroup C: >=1:128: Day 31 | 100 (94.4 to 100) |
| Serogroup Y: >=1:8: Day 1 | 55.9 (42.4 to 68.8) |
| Serogroup Y: >=1:128: Day 1 | 44.1 (31.2 to 57.6) |
| Serogroup Y: >=1:8: Day 31 | 100 (94.4 to 100) |
| Serogroup Y: >=1:128: Day 31 | 100 (94.4 to 100) |
| Serogroup W: >=1:8: Day 1 | 61.9 (48.8 to 73.9) |
| Serogroup W: >=1:128: Day 1 | 41.3 (29.0 to 54.4) |
| Serogroup W: >=1:8: Day 31 | 100 (94.4 to 100) |
| Serogroup W: >=1:128: Day 31 | 100 (94.4 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A | 83.3 (70.7 to 92.1) |
| Serogroup C | 98.3 (91.1 to 100) |
| Serogroup Y | 98.3 (90.8 to 100) |
| Serogroup W | 100 (94.2 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). rSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:32 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.
| Percentage of participants | MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A | 83.3 (70.7 to 92.1) |
| Serogroup C | 98.3 (91.1 to 100) |
| Serogroup Y | 98.3 (90.8 to 100) |
| Serogroup W | 100 (94.2 to 100) |
Geometric Mean Concentrations (GMCs) of anti-tetanus toxoid antibodies was measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent assay.
| International units/milliliter | MenACYW Conjugate Vaccine |
|---|---|
| Day 1 | 0.642 (0.482 to 0.854) |
| Day 31 | 8.56 (6.17 to 11.9) |
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.
| Participants | MenACYW Conjugate Vaccine |
|---|---|
| Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 0 |
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site tenderness, injection site erythema and injection site swelling. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability.
| Participants | MenACYW Conjugate Vaccine |
|---|---|
| Solicited injection site reaction | 24 |
| Solicited systemic reaction | 35 |
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.
| Participants | MenACYW Conjugate Vaccine |
|---|---|
| Number of Participants With Unsolicited Adverse Events | 23 |
An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.
| Participants | MenACYW Conjugate Vaccine |
|---|---|
| SAEs | 1 |
| AESIs | 1 |
Collected over AEs, SAEs and all-cause mortality (deaths) were collected from vaccination (Day 1) up to 30 days post vaccination, 31 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MenACYW Conjugate Vaccine | 0/69 (0%) | 1/69 (1.4%) | 45/69 (65.2%) |
| Event | MenACYW Conjugate Vaccine |
|---|---|
| Febrile ConvulsionNervous system disorders | 1/69 |
| Event | MenACYW Conjugate Vaccine |
|---|---|
| IrritabilityPsychiatric disorders | 22/69 |
| Injection Site PainGeneral disorders | 21/69 |
| Decreased AppetiteMetabolism and nutrition disorders | 14/69 |
| CryingGeneral disorders | 14/69 |
| PyrexiaGeneral disorders | 14/69 |
| SomnolenceNervous system disorders | 13/69 |
| VomitingGastrointestinal disorders | 13/69 |
| DiarrhoeaGastrointestinal disorders | 5/69 |
| NasopharyngitisInfections and infestations | 4/69 |
| Injection Site ErythemaGeneral disorders | 4/69 |
Baseline characteristics were evaluated for study participants with data in case report form (CRF).
| Age, Continuous(months) | MenACYW Conjugate Vaccine |
|---|---|
| Mean | 14.3 ± 1.50 |
| Sex: Female, Male(Participants) | MenACYW Conjugate Vaccine |
|---|---|
| Female | 34 |
| Male | 37 |
| Race and Ethnicity Not Collected(Participants) | MenACYW Conjugate Vaccine |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2023 to primary completion in Sep 2024, 12 months.
Results were first posted in Sep 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →